Abstract: The present invention relates to compound of Formula 1 for use in treating IPF, by reducing collagen deposition in lungs, attenuating the fibrotic marker's expression (in IPF cell-lines Bleomycin induced rat lungs) and improving the bleomycin induced pathological changes in rat lungs, and ARDS, by reducing the cytokine storm. The invention also relates to compound of Formula 1 for use in treating various fibrotic disorders like lung injuries caused by virus or bacterial infections, cardiac, hepatic and kidney fibrosis.

Abstract: The present invention relates to a synthetic method for the preparation of phytosteryl ferulate using ferulic acid and phytosterols (isolated from soybean oil deodorizer distillate) comprising of (a) acetylation of ferulic acid to ferulic acid acetate; (b) esterification of ferulic acid acetate with phytosterols to obtain phytosteryl ferulate acetate; (c) deprotection of phytosteryl ferulate acetate to phytosteryl ferulate. The phytosteryl ferulate was evaluated for hypocholesteremic activity in hamsters in comparison with that of natural oryzanol isolated from rice bran oil soap stock. This study confirmed that the phytosteryl ferulate significantly lowers the elevated cholesterol levels and also interferes with the absorption of cholesterol and the effect is comparable with that of natural oryzanol and is useful as nutraceutical/food supplement. Hence phytosteryl ferulate is a potential substitute for natural oryzanol for several applications.

Abstract: A method is provided for controlling the operating temperature of a catalytic reactor using a closed-loop system that provides for varying the reactor input and other operating parameters in order to maintain the operating temperature of the reactor at or near the initial setpoint temperature for operation of the reactor. In one example, maximum and minimum operating temperatures with a catalytic partial oxidation reactor are controlled, as well as maintaining control over the corresponding minimum required ratio of oxygen atoms to carbon atoms, such that the operating temperature within the reactor is maintained below the material limits but above threshold temperatures for coking.

Abstract: The present invention provides compounds and pharmaceutically acceptable salts thereof methods for synthesizing thienopyridines and methods for inhibiting TNF-? activity for the treatment of cancer, asthma, arthritis, diabetes and inflammation. Provided are compounds of formula (I).

Abstract: A novel ?-carboline guanidine derivative tiruchenduramine (1) and its derivatives are disclosed. These compounds have been isolated from the Indian ascidian Synoicum macroglossum. These compounds are useful in the treatment of diabetic disorder by providing inhibition of ? (alpha)glucosidase.

Abstract: A novel ?-carboline guanidine derivative tiruchenduramine (1) and its derivatives are disclosed. These compounds have been isolated from the Indian ascidian Synoicum macroglossum. These compounds are useful in the treatment of diabetic disorder by providing inhibition of ? (alpha)glucosidase.

Abstract: The invention provides a novel herbal formulation useful for the treatment of skin disorders and comprising two or more plant extracts selected from Tagetes erecta, Moringa oleifera, Ocimum sanctum, Tridax procumbens, Aloe vera, and Gum olibanum together with conventional additives.

Abstract: The invention provides a herbal formulation useful as a therapeutic and cosmetic applications for the treatment of general skin disorders, said composition comprising at least two or more plant extracts in the form of oil or powder or mixtures thereof, the said plants extracts being selected from the group consisting of Gymnena sylvestrae water extract 3 to 6 wt. %; Tridax procumbens water extract 3 to 6 wt. %; its methanolic extract 4 to 6 wt. %, Allium sativum oilhexane extract 1 to 3 wt. %; dried juice of Aloe vera 2 to 6 wt. %; Gum olibanum powder in the natural form 4 to 7 wt. %; Gum olibanum resinoid or its organic extract 3 to 8 wt. %; and resinoid free Gum olibanum meal 5 to 10 wt. %., optionally, including any drug having anti-inflammatory and wound healing property or mixture thereof, the said drug being selected from the group consisting of Disclofenac sodium 1-3 wt. %, Salicyclic acid 1 to 4 wt. %, Piroxicam 1 to 2 wt. %, Turmeric powder 0.1 to 1 wt.

Abstract: The invention provides a herbal formulation useful as a therapeutic and cosmetic applications for the treatment of general skin disorders, the composition comprising at least two or more plant extracts in the form of oil or powder or mixtures thereof, the plant extracts being selected from the group consisting of Gymnena sylvestrae water extract 3 to 6 wt. %; Tridax procumbens water extract 3 to 6 wt. %; its methanolic extract 4 to 6 wt. %, Allium sativum oil hexane extract 1 to 3 wt. %; dried juice of Aloe vera 2 to 6 wt. %; Gum Olibanum powder in the natural form 4 to 7 wt. %; Gum Olibanum resinoid organic solvent extract 3 to 8 wt. %; and resinoid free Gum Olibanum meal 5 to 10 wt. %., optionally, including any drug having anti-inflammatory and wound healing property or mixture thereof, the drug being selected from the group consisting of Disclofenac sodium 1-3 wt. %, Salicyclic acid 1 to 4 wt. %, Piroxicam 1 to 2 wt. %, Turmeric powder 0.1 to 1 wt.